Metabolic and Bariatric Surgery Utilization in the Era of Glucagon-Like Peptide-1 Receptor Agonists among Adolescents versus Adults
Sarah Messiah, D. Ernest, Folefac Atem, Faisal G. Qureshi, M. Sunil Mathew, Jackson Francis, Alicia Wheelington, Marlyn Allicock, Bethany R. Cartwright, Benjamin E. Schneider, Nestor de la Cruz‐Muñoz, Steven E. Lipshultz, Ildiko Lingvay, Jaime P. Almandoz, Sarah E. Barlow
Abstract
This cross-sectional study analyzed adolescent metabolic and bariatric surgery (MBS) utilization before and after glucagon-like peptide-1 receptor agonist (GLP-1RA) medication approval, comparing trends across race and ethnic groups. Although both MBS and GLP-1RA are effective weight management strategies, adolescent MBS utilization increased, while adult rates declined from 2021 through 2023.
Topics & Concepts
MedicineGlucagon-like peptide 1 receptorAgonistReceptorInternal medicineIntensive care medicineBariatric Surgery and OutcomesDiet and metabolism studiesPharmacology and Obesity Treatment